Group 1 - The core viewpoint of the report is that Weigao Co., Ltd. maintains an "overweight" rating with a target price of HKD 7.84, following its plan to acquire 100% equity of Weigao Purui, positioning itself as the controlling shareholder of Weigao Blood Net and enhancing its role as a flagship platform for medical devices within the group [1] - The acquisition is expected to be completed in the second to third quarter of 2026, with the final transaction plan announced on January 5, 2026, and the assessment value of Weigao Purui's 100% equity set at CNY 8.511 billion [1] - Weigao Blood Net's projected net profits for 2023, 2024, and the first nine months of 2025 are CNY 483 million, CNY 581 million, and CNY 486 million respectively, with committed net profits for 2026, 2027, and 2028 at CNY 640 million, CNY 720 million, and CNY 784 million respectively [1] Group 2 - The upstream biopharmaceutical market is expected to grow rapidly, with a market size of CNY 21.2 billion in 2024 and a compound annual growth rate (CAGR) of 11.5% from 2024 to 2030, indicating significant opportunities for domestic substitution [2] - Weigao Blood Net has established a product line for upstream biopharmaceutical filtration, while Weigao Purui possesses extensive customer resources in the biopharmaceutical sector, suggesting potential synergies post-acquisition [2] - The transaction will result in Weigao Co., Ltd. holding 52.10% of Weigao Blood Net's shares, thereby becoming its controlling shareholder and consolidating financial statements, further clarifying its positioning as the flagship platform for medical devices under the Weigao brand [3]